• Advertise
  • About us
  • Terms and Conditions
  • Contact us
Thursday, June 19, 2025
Australian Times News
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia
No Result
View All Result
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia
No Result
View All Result
Australian Times News
No Result
View All Result
Home News

Pfizer vaccine has just been approved: here’s what the next few months will look like

The UK has become the first country to approve the Pfizer/BioNTech vaccine for widespread use. The government has ordered 40 million doses and the first batch of 800,000 doses is expected to be shipped from Belgium – where the vaccine is being made – in the next couple of days.

The Conversation by The Conversation
03-12-2020 18:05
in News
We don’t know if the vaccines stop transmission

We don’t know if the vaccines stop transmission Photo by Alex Mecl on Unsplash

Manal Mohammed, University of Westminster

The UK has become the first country to approve the Pfizer/BioNTech vaccine for widespread use. The government has ordered 40 million doses and the first batch of 800,000 doses is expected to be shipped from Belgium – where the vaccine is being made – in the next couple of days. It will be enough to immunise 400,000 people (two doses per person).

The UK drugs regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), is also started a rolling review of other vaccines in late-stage human trials, such as the AstraZeneca/Oxford vaccine and the Moderna vaccine. If these vaccines also meet the very high efficacy and safety standards set by the agency, they too will be approved for mass rollout.

The fastest a vaccine has ever been developed is the mumps vaccine, which took a mere four years from concept to market. These latest vaccines beat that record by some margin – taking less than a year to develop. But that doesn’t mean any corners have been cut.

The MHRA has pored over the records of over 40,000 vaccine trial participants from diverse backgrounds. The efficacy of the vaccine – that is, how effective it is at preventing symptomatic COVID-19 under trial conditions – is 95%. (That figure is expected to fall slightly under real-world conditions.) And there were no serious side effects, although these will continue to be monitored as the vaccine is rolled out.

It is expected that healthcare workers will receive the vaccine first as they are one of the most vulnerable groups. Also, hospitals have the ultra-cold freezers needed to store the vaccine – so, from a logistics standpoint, it’s a good place to start.

Don’t ditch the mask just yet

This is all fantastic news and a good reason to be optimistic about the future. But Peter Openshaw, a professor of experimental medicine at Imperial College London, said it would be a “terrible mistake” to ease up on COVID control measures at this juncture.

AlsoRead...

Leading with Trust: Why Quality still wins in the AI Era

Leading with Trust: Why Quality still wins in the AI Era

5 June 2025
Why Australian Investors are Betting on the Aviation Maverick Louis Belanger-Martin

Why Australian Investors are Betting on the Aviation Maverick Louis Belanger-Martin

28 May 2025

So don’t throw away your mask and hug your gran just yet. A report from The Royal Society, the world’s oldest independent scientific academy, says that restrictions are likely to remain in place for some months yet – maybe even a year.

When you get the COVID vaccine, you should not expect immediate protection against infection. White blood cells known as B lymphocytes first need to detect the antigen in the vaccine and then generate specific antibodies against it. If you get exposed to coronavirus, these antibodies latch onto the virus and neutralise it.

The response from your immune system, generated by the B lymphocytes, is known as the primary response and it takes about two weeks to kick in. So for two weeks after getting the jab you are still at risk of getting ill from COVID.

Also, many COVID vaccines require two jabs to provide full protection. And the interval between the jabs varies from 21 to 28 days. So the vaccine will take about six weeks after the first jab to provide full protection against COVID-19 disease.

We don’t know if the vaccines stop transmission

Although the vaccines in late-stage trials seem to be highly effective at preventing symptomatic COVID, we can’t yet be sure that they prevent transmission of the virus.

For this, we would need a vaccine that provides so-called sterilising immunity. This is where immune cells can bind to the virus to prevent it from entering cells where it can start to replicate. So even six weeks after receiving the first jab, you may still get infected with the coronavirus – even if you don’t get sick.

Studies from the preclinical phase of the Oxford vaccine found that rhesus macaques that were immunised with the vaccine were protected from serious disease and had no evidence of lung damage. But they still had coronavirus infection in their upper-respiratory tract and virus shedding from their noses. If this is the same with humans, it would suggest that while they will be protected from symptomatic disease, they might still spread the virus.

At this stage, we don’t know if the Pfizer or Moderna vaccines stop transmission either, although further studies will hopefully tease this out.

Also, if you have been vaccinated, there is a small chance – at least one in twenty – that the vaccine won’t protect you. So even if you have been vaccinated – and full rollout may not be complete till the summer of 2021 – you should still wear a mask, work from home if you can, and practice social distancing. As for good hand hygiene, let’s try to keep that going – viruses, including probably SARS-CoV-2, will always be among us.

Manal Mohammed, Lecturer, Medical Microbiology, University of Westminster

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Tags: SB001
DMCA.com Protection Status

SUBSCRIBE to our NEWSLETTER

[mc4wp_form id=”2384248″]

Don't Miss

Leading with Trust: Why Quality still wins in the AI Era

by Pauline Torongo
5 June 2025
Leading with Trust: Why Quality still wins in the AI Era
Business & Finance

If you're leading a software team today, you've likely noticed the shift: faster feature rollouts, routine automation, and AI taking...

Read more

How to Save on Airport Parking: Budget Tips Every Traveller Should Know

by Fazila Olla-Logday
3 June 2025
How to Save on Airport Parking
Travel

Saving money on airport parking can be a challenge,but here are some budget friendly tips to help you navigate.

Read more

Why Australian Investors are Betting on the Aviation Maverick Louis Belanger-Martin

by Pauline Torongo
28 May 2025
Why Australian Investors are Betting on the Aviation Maverick Louis Belanger-Martin
Business & Finance

Bélanger-Martin’s ambitions stretch beyond redefining inflight comfort—they’re rooted in resurrecting the romance of supersonic travel with a modern twist.

Read more

Why a Gluten Free Hamper is simply the Best Gift for a Coeliac

by Fazila Olla-Logday
22 May 2025
Gluten Free Hamper
at

Buying a thoughtful gift can be tricky at the best of times, but when someone has dietary restrictions like coeliac...

Read more

Biela.dev is quietly becoming the Infrastructure Layer for the Next Internet

by Pauline Torongo
15 May 2025
Biela.dev is quietly becoming the Infrastructure Layer for the Next Internet
Technology

Biela.dev is not merely a consumer app; it is infrastructure. It could be a layer that powers the next generation...

Read more

The Battle for the Premier League’s Fifth Champions League Spot: Who Will Prevail?

by Fazila Olla-Logday
8 May 2025
Premier-Leagues-Fifth-Champions-League-Janosch-Diggelmann-Unsplash
at

As the Premier League season nears its climax, the race for the coveted Champions League places is tighter and more...

Read more

The Predictive Infrastructure: How BOF’s Neuro Finance System Reengineers Market Forecasting

by Pauline Torongo
5 May 2025
The Predictive Infrastructure: How BOF’s Neuro Finance System Reengineers Market Forecasting
Business & Finance

As global markets become more complex and volatile, BOF Investments has developed Neuro Finance, a predictive system that combines machine...

Read more
Load More

Copyright © Blue Sky Publications Ltd. All Rights Reserved.
australiantimes.co.uk is a division of Blue Sky Publications Ltd. Reproduction without permission prohibited. DMCA.com Protection Status

  • About us
  • Write for Us
  • Advertise
  • Contact us
  • T&Cs, Privacy and GDPR
No Result
View All Result
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia

Copyright © Blue Sky Publications Ltd. All Rights Reserved.
australiantimes.co.uk is a division of Blue Sky Publications Ltd. Reproduction without permission prohibited. DMCA.com Protection Status